In the first five months of 2025, retail sales of erectile dysfunction medications in Russia surpassed 3.9 billion rubles, including VAT, marking a 12,3% increase compared to the same period last year. In natural units, over 6 million packages were sold, an 8.7% rise from January to May 2024. Data from RNC Pharma indicates that nearly all of these top ten drugs are generics.
According to experts, the current market dynamics are shifting amid notable structural changes. Following the withdrawal of several original drugs from the Russian market in 2023, the volume of ruble sales in this category decreased by 12.8%. However, generic drugs were able to offset this decline. Although revenue decreased, physical sales continued to increase.
Another notable trend is the decrease in the average cost of therapy. From January to May of 2025, the average price of one package of the drug was 643 rubles, which is an 18% decrease from three years prior. This decrease is due to a change in market structure favoring more affordable generics and general price dynamics in the pharmaceutical sector.
According to the results from the first five months of this year, there are 38 brands of erectile dysfunction drugs on the Russian market, most of which are domestically produced. Severnaya Zvezda led the way, providing 46% of sales in physical terms and over 36% of the market in rubles. The manufacturer offers four products based on sildenafil, tadalafil, and dapoxetine.
Meanwhile, unbranded sildenafil drugs remain in high demand. These drugs are produced by 11 manufacturers, the most notable of which is Severnaya Zvezda. Various forms of tadalafil occupy the second position, together holding a 23.6% market share. The third place belongs to the drug Dynamico (sildenafil) from Teva Pharmaceutical, which received 14% in monetary terms.
The Tadanord, produced by Severnaya Zvezda, is one of the new products that has shown significant sales growth. Analysts report that nearly all drugs on the market are produced by Russian manufacturers, indicating full import substitution in this pharmaceutical market segment.
